G
Galvanize Therapeutics
Designs and develops pulsed electric field systems to achieve meaningful, and lasting therapeutic outcomes for patients
About Galvanize Therapeutics
Galvanize is a pioneering startup operating in the medical device technology sector, specifically focusing on energy-based solutions. The company's primary product is the Aliya platform, a groundbreaking technology designed to influence biological processes. Galvanize's initial focus is on chronic bronchitis, cardiac arrhythmias, oncology, and drug delivery, aiming to transform energy into therapeutic solutions.
The company's target market includes healthcare providers and patients suffering from these chronic conditions. Galvanize operates in the medical device industry, a sector known for its high potential for growth and innovation. The business model revolves around the development, marketing, and sale of its Aliya platform and other energy-based medical devices.
Revenue is generated through the sale of these devices to healthcare providers and institutions. The company's leadership team, including Senior Vice President of Sales & Marketing, Michael, brings extensive commercial experience in the Electrophysiology market, which is expected to contribute to the company's growth and market penetration.
Galvanize is backed by ATP (Apple Tree Partners), a prominent life sciences venture capital firm. This partnership provides Galvanize with financial support and strategic guidance, enhancing its potential for success in the competitive medical device market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- San Carlos, United States
- Employees
- 171
- Open positions
- 10
- Dealroom signal
- 91.8/100
- Industry
- Health, Energy
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Oncology, Cardiology and cardiovascular, Respiratory, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Sep 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Sep 2025 | $100M | $400M | Norwest Venture Partners · Janus Henderson Investors · Ally Bridge Group · T. Rowe Price | ↗ |
| SERIES BOther financing | Sep 2022 | $100M | $400M | Intuitive Surgical · Fidelity Investments · Apple Tree Partners · Gilmartin Capital | ↗ |
Growth signals
Latest recorded traffic for Galvanize Therapeutics is 2.7K monthly website visits, up 3.8% over the last three months. Galvanize Therapeutics's team grew 12.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gala TherapeuticsMenlo Park, United StatesInnovative bronchoscopic therapy reducing mucus cells in chronic bronchitis patients with non-thermal pulsed electric fields
→
Galaxy MedicalSan Carlos, United StatesInnovative Pulsed Electric Field technology for treating cardiac arrhythmias
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Fidelity Investments
Intuitive Surgical
Apple Tree Partners
Gilmartin Capital
Series B and later8 investors entered at this stage
Sofinnova Partners
Norwest Venture PartnersJanus Henderson Investors
Ally Bridge Group
T. Rowe Price- PFPerceptive Xontogeny Venture Fund
Elevage Medical Technologies
Longaeva Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Galvanize Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Galvanize Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







